Das Medizinportal
Menü

Literatur:

Die suprachoroidale Hydrogelplombe – eine Revolution in der Buckelchirurgie
(S. 16-20)

K. Boden, K. Januschowski, P. Szurman

1. Custodis E. Bedeutet die Plombenaufnähung auf die Sklera einen Fortschritt in der operativen Behandlung der Netzhautablösung. Ber Dtsch Ophthalmol Ges 58. 1953;
2. Abdullah AS, Jan S, Qureshi MS, Khan MT, Khan MD. Complications of conventional scleral buckling occuring during and after treatment of rhegmatogenous retinal detachment. J Coll Physicians Surg Pakistan. 2010;20(5):321–6.
3. Ah-Fat FG, Sharma MC, Majid M a, McGalliard JN, Wong D. Trends in vitreoretinal surgery at a tertiary referral centre: 1987 to 1996. Br J Ophthalmol. 1999;83(4):396–8.
4. Wong D, Billington BM, Chignell AH. Pars plana vitrectomy for retinal detachment with unseen retinal holes. Graefes Arch Clin Exp Ophthalmol. 1987;225(4):269–71.
5. Feltgen N, Weiss C, Wolf S, Ottenberg D, Heimann H. Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment study (SPR Study): Recruitment list evaluation. Study report no. 2. Graefe’s Arch Clin Exp Ophthalmol. 2007;245(6):803–9.
6. Mittl RN, Tiwari R. Suprachoroidal injection of sodium hyaluronate as an “internal” buckling procedure. Ophthalmic Res. 1987;19(5):255–60.
7. Poole T a, Sudarsky RD. Suprachoroidal implantation for the treatment of retinal detachment. Ophthalmology. 1986;93(11):1408–12.
8. El Rayes EN. Suprachoroidal buckling. Dev Ophthalmol. 2014;54:135–46.
9. El Rayes EN, Mikhail M, Cheweiky H El, Elsawah K, Maia A. Suprachoroidal buckling for the managment of rhegmatodenous retinal detachments secondary to peripheral retinal breaks. Retina. 2016;0(0):18.
10. Oshima Y, El Rayes EN, Matsumura N, Sakaguchi H. Suprachoroidal buckling technique. Retin Today. 2013;MAY(JUNE/-):71–6.
11. Szurman P, Januschowski K, Boden KT, Szurman GB. A modified scleral dissection technique with suprachoroidal drainage for canaloplasty. Graefe’s Arch Clin Exp Ophthalmol. 2016;254(2):351–4.
12. Seuthe AM, Ivanescu C, Leers S, Boden K, Januschowski K, Szurman P. Modified canaloplasty with suprachoroidal drainage versus conventional canaloplasty—1-year results. Graefe’s Arch Clin Exp Ophthalmol. 2016;254(8):1591–7.
13. Binder S, Stanzel B V., Krebs I, Glittenberg C. Transplantation of the RPE in AMD. Vol. 26, Progress in Retinal and Eye Research. 2007. p. 516–54.
14. Bindewald  a, Roth F, Van Meurs J, Holz FG. Transplantation of retinal pigment pithelium (RPE) following CNV removal in patients with AMD. Techniques, results, outlook. Ophthalmologe. 2004;101(9):886–94.
15. Heussen FM a, Fawzy NF, Joeres S, Lux  a, Maaijwee K, Meurs JC, et al. Autologous translocation of the choroid and RPE in age-related macular degeneration: 1-year follow-up in 30 patients and recommendations for patient selection. Eye (Lond). 2008;22(6):799–807.
16. Treumer F, Klatt C, Roider J. [Autologous RPE-choroid translocation in exudative AMD. A case series of 10 consecutive patients]. Ophthalmologe. 2007;104(9):795–802.
17. Mazinani B, Baumgarten S, Schiller P, Agostini H, Helbig H, Limburg E, et al. Vitrectomy with or without encircling band for pseudophakic retinal detachment: a multi-centre, three-arm, randomised clinical trial. VIPER Study Report No. 1-design and enrolment. Br J Ophthalmol. 2016;100(3):405–10.
18. Heimann H, Hellmich M, Bornfeld N, et al. Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment (SPR Study): Design issues and implications SPR Study report no. 1. Vol. 239, Graefe’s Archive for Clinical and Experimental Ophthalmology. 2001. p. 567–74.
19. Hütz WW, Eckhardt HB, Kohnen T. Comparison of viscoelastic substances used in phacoemulsification. J Cataract Refract Surg. 1996;22(7):955–9.
20. Hsu WC, Ritch R, Krupin T, Chen HSL. Tissue bioengineering for surgical bleb defects: An animal study. Graefe’s Arch Clin Exp Ophthalmol. 2008;246(5):709–17.
21. Zelefsky JR, Hsu W, Ritch R. Biodegradable collagen matrix implant for trabeculectomy. Expert Rev Ophthalmol. 2008;3(6):613–7.
22. Chen HSL, Ritch R, Krupin T, Hsu WC. Control of filtering bleb structure through tissue bioengineering: An animal model. Investig Ophthalmol Vis Sci. 2006;47(12):5310–4.
23. Rosentreter A, Schild  a M, Jordan JF, Krieglstein GK, Dietlein TS. A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma. Eye (Lond). 2010;24(9):1449–57.
24. Papaconstantinou D, Georgalas I, Karmiris E, Diagourtas A, Koutsandrea C, Ladas I, et al. Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: A pilot study. Acta Ophthalmol. 2010;88(1):80–5.
25. Szurman P, Boden K, Januschowski K. Suprachoroidal Hydrogel Buckling as a Surgical Treatment of Retinal Detachment: Biocompatibility and First Experiences. Retina. 2016;Sep;36(9):1786–90.

Innovative Lösungen in der AMD-Versorgung (S. 26-28)
J. Bouws
1. Finger, RP & Holz, FG 2014, „Versorgung von Patienten mit neovaskulärer altersabhängiger Makuladegeneration in Deutschland“, Der Ophthalmologe, 111(5): 438-442.
2. Spital, G et al. 2016,“SD-OCT Befundung im Praxisalltag im Vergleich zur standardisierten Auswertung durch Reading Center – Baseline Daten der ORCA-Studie“, 29. Jahrestagung der Retinologischen Gesellschaft, Berlin.
3. Wolf, A & Kampik, A 2014, “Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research”, Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie, 252(4): 647-655.
4. Roider, H et al. 2014, „Die Behandlung der altersbedingten Makuladegeneration im Alltag – warum schneiden wir im europäischen Vergleich schlechter ab?“, Kongress-Pressekonferenz im Rahmen des 112. Kongresses der Deutschen Ophthalmologischen Gesellschaft (DOG), Leipzig.
5. Heimes, B et al. 2016, “Compliance von Patienten mit altersabhängiger Makuladegeneration unter Anti-VEGF-Therapie“, Der Ophthalmologe, (11): 1-8.

Makulalinse – die Lupe im Auge (S. 29-31)
G. Scharioth
1. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398.
2. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Archives of Ophthalmology. 2004;122(4):477–485.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. 2006;355(14):1419–1431.
4. DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398.
5. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548.
6. Lipshitz I, Loewenstein A, Reingewiirtz M,  et al. An intraocular telescopic lens for macular degeneration. Ophthalmic Surg Lasers. 1997 Jun;28(6):513-7.
7. Lane SS, Kuppermann BD, Fine IH, et al. A prospective multicenter clinical trail to evaluate safety and effectiveness of the implantable miniature telescope. Am J Ophthalmol. 2004 Jun;137(6):993-1001
8. Agarwal AI, Lipshitz I, Jacob S, et al. Mirror telescopic intraocular lens for age-related macular degeneration: design and prelimanary clinical results of the Lipshitz macular implant. J Cataract Refarct Surg. 2008 Jan;34(I):87-94
9. Qureshi MA, Robbie SJ, Tabernero J, Artal P. Injectable intraocular telescope: Pilot study. J Cataract Refract Surg. 2015 Oct;41(10):2125-35.
10. Sauder G, Cordes A. Scope of applications and experience record with a new generation of Add-on IOLs: The A4W lens. Ophthalmo-Chirurgie 2012;24 (Suppl.2):1-6
11. Scharioth GB. New add-on intraocular lens for patients with age-related macular degeneration. J Cataract Refract Surg. 2015 Aug;41(8):1559-63.
12. Srinivasan S. Scharioth G.B. Rhiel  A Implantation of Scharioth macular lens in patients with age-related macular degeneration: results of a prospective European multicenter clinical trial, Poster at ESCRS 2016, Copenhagen, Denmark
13. Nekolova J, Rozsival P, Sin M, Jiraskova N.  Scharioth Macula Lens: A new intraocular implant for low-vision patients with stabilized maculopathy- first experience. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Jun;161(2):206-209

Update – Aus den Unternehmen
Rolle der Inflammation beim DMÖ (Pharm Allergan, S. 44/45)
1. Kongress der Deutschen Ophthalmochirurgen (DOC). DOC-Abend-Symposium der Pharm-Allergan GmbH, Intravitreale medikamentöse Therapie und Diagnose – heute und morgen, Donnerstag, 11. Mai 2017, 19.00-20.30 Uhr, Nürnberg.
2. Totan Y et al. Curr Eye Res 2016; 41(1): 107–113.
3. Wecker T et al. Br J Ophthalmol 2017; 101: 353–359.
4. Escobar-Barranco JJ et al. Ophthalmologica 2015; 233: 176–185.
5. Medeiros MD et al. Opthalmologica 2014; 231: 141–146.
6. Guigou S et al. J Fr Ophthalmol 2014; 38: 480–485.
7. Fachinformation Ozurdex(R), Stand März 2015.
8. Aknin I, et al. Ophthalmologica. 2016; 235(4): 187–8.
9. Sivaprasad S et al. Clin Ophthalmol 2016; 10: 939–946.
10. Schmidt-Erfurth U et al. Ophthalmologica 2017; 237: 185–222
11. Gonzalez VH et al. Am J Ophthalmol 2016; 172: 72–79.
12. Khan Z et al. Opthalmic Surg Lasers Imaging Retina 2007; 48(2): 160–166.
13. Vujosevic S et al. J Diabetes Res 2013; 491835.
14. Vujosevic S et al. Acta Ophthalmol 2016; 95(5): 464–471.